Chief Executive Officer
Jeff has more than 20 years experience in the bioscience and industrial sectors. He has started and led companies that have developed numerous novel products in chemical and biological analysis, drug delivery, and diagnostics. Prior to Fluxion, Jeff served as President and CEO of Eksigent Technologies (acquired by Danaher), a leading supplier of microfluidic platforms for bio-analytical and medical device applications. Prior to Eksigent, Jeff held management positions in numerous functions at Raychem and Pall Corporation. Jeff received his BS from Cornell University in Chemical Engineering and graduated from the Program for Management Development at Harvard Business School.
Cristian Ionescu-Zanetti, Ph.D.
Chief Technology Officer
Cristian is a co-founder of Fluxion Biosciences and has been developing the company’s technology since its inception. Cristian’s passion is bringing ideas from concept to product. Together with Fluxion’s talented engineers and scientists, he’s brought three different instrumentation platforms to market. They are being used by clinical, translational, and basic researchers, and have contributed to hundreds of publications and clinical studies.
Cristian holds a PhD in Physics from UC Santa Cruz and was a researcher at UC Berkeley, where key parts of Fluxion’s foundational intellectual property were developed. Cristian has authored over 40 journal publications.
Ali Yehia, PH.D.
VP Electrophysiology and Drug Screening
Ali is an experienced electrophysiologist with an extensive background in ion channels and automated patch clamp. He has been working in the automated patch clamp industry for more than 11 years. Before joining Fluxion, he worked at Sophion Bioscience for more than 5 years, first as an Application Scientist and Scientific Business Manager and ending as the Director of Sales for North America. Prior to this he held different leadership roles at the Medical Information Technology at McGill University. Ali received his PhD in Physiology (Cardiac Electrophysiology) from McGill University in Montreal, Canada and his BSc in General Biology from the American University of Beirut.
Bryan Haines, Ph.D.
Global Director, BioFlux Sales and Support
Bryan is an accomplished molecular biologist with more than 15 years of experience in the field. Before joining Fluxion he worked at The Buck Institute for Research on Aging and the University of Nevada on mechanisms of brain injury, neuroprotection and drug discovery. At Fluxion, Bryan has led BioFlux product development and supported novel research using BioFlux in the areas of vascular biology, cancer, immunology, and microbiology. Bryan completed his BSc in Biochemistry from Virginia Tech, MBA from Mount Saint Mary’s University, and earned his PhD in Cell and Molecular Biology at the University of Hawaii.